Jason R. Westin
YOU?
Author Swipe
View article: Clinical Trial Success Rate in Lymphoma: Fate of Trials and Agents from 2000 to 2019
Clinical Trial Success Rate in Lymphoma: Fate of Trials and Agents from 2000 to 2019 Open
While previous studies have examined the drug development and clinical trial success rates in oncology, a comprehensive analysis of the development success rate in lymphoma has not been performed. We thus analyzed lymphoma trials initiated…
View article: 503 Multi-omics analysis of the ZUMA-7 study reveals 7 types of tumor microenvironments in large B-cell lymphoma featuring mechanisms of resistance to CAR T cell therapy & strategies for improving outcome
503 Multi-omics analysis of the ZUMA-7 study reveals 7 types of tumor microenvironments in large B-cell lymphoma featuring mechanisms of resistance to CAR T cell therapy & strategies for improving outcome Open
View article: Multi-modal spatial characterization of tumor immune microenvironments identifies targetable inflammatory niches in diffuse large B cell lymphoma
Multi-modal spatial characterization of tumor immune microenvironments identifies targetable inflammatory niches in diffuse large B cell lymphoma Open
View article: Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial Open
PURPOSE Prognosis for patients with refractory/relapsed large B-cell lymphoma (LBCL) considered ineligible for curative-intent therapy is poor. The combination of mosunetuzumab, a T-cell–engaging bispecific antibody, and polatuzumab vedoti…
View article: Supplementary Figure S3 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma
Supplementary Figure S3 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma Open
Associations between cytokine changes and progression
View article: Supplementary Figure S4 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma
Supplementary Figure S4 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma Open
UMAP from single cell RNA sequencing
View article: Data from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma
Data from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma Open
Purpose:SIRPα+ macrophages can mediate resistance to lenalidomide and rituximab in patients with B-cell non-Hodgkin lymphoma (B-NHL). Evorpacept (ALX148) is a novel CD47 blocker that abrogates interactions between lymphoma cells and SIRPα+…
View article: Supplementary Protocol S1 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma
Supplementary Protocol S1 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma Open
Eligibility criteria and DLT definition
View article: Supplementary Table S1 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma
Supplementary Table S1 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma Open
Representativeness of Study Participants
View article: Supplementary Table S3 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma
Supplementary Table S3 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma Open
Sample summary and quality control
View article: Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy
Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy Open
Background Recent data have suggested that germline genetic aberrations can affect outcomes in patients with large B-cell lymphoma (LBCL) treated with chimeric antigen receptor T-cell therapy (CART). However, a comprehensive analysis of ge…
View article: Supplementary Figure S2 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma
Supplementary Figure S2 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma Open
Changes in T cells and myeloid cells during treatment
View article: Supplementary Table S2 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma
Supplementary Table S2 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma Open
Differential gene expression and progression
View article: Supplementary Figure S1 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma
Supplementary Figure S1 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma Open
Laboratory trends during treatment
View article: Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma
Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma Open
PURPOSE Large B-cell lymphomas (LBCLs) are curable, but patients with residual disease after therapy invariably experience progression. Ultrasensitive methods to detect circulating tumor DNA (ctDNA) as minimal residual disease (MRD) may im…
View article: Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial Open
This phase II trial aims to determine the efficacy and safety of frontline acalabrutinib, lenalidomide and rituximab for patients with advanced stage follicular lymphoma (FL) and high tumor burden. The primary endpoint was best complete re…
View article: A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma
A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma Open
Purpose: SIRPα+ macrophages can mediate resistance to lenalidomide and rituximab in patients with B-cell non-Hodgkin lymphoma (B-NHL). Evorpacept (ALX148) is a novel CD47 blocker that abrogates interactions between lymphoma cells and SIRPα…
View article: A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma Open
Follicular lymphoma (FL) has a clinical course that is often characterized by high response rates to first-line therapy, followed by multiple relapses over a prolonged natural history. Currently, there are multiple possible approaches to f…
View article: LBA3 | MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN IS SUPERIOR TO R‐GemOx IN TRANSPLANT‐INELIGIBLE PATIENTS WITH R/R LBCL: PRIMARY RESULTS OF THE PHASE III SUNMO TRIAL
LBA3 | MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN IS SUPERIOR TO R‐GemOx IN TRANSPLANT‐INELIGIBLE PATIENTS WITH R/R LBCL: PRIMARY RESULTS OF THE PHASE III SUNMO TRIAL Open
View article: 838 | A PHASE 1 TRIAL OF NX‐2127, A FIRST‐IN‐CLASS BTK DUAL‐TARGETED PROTEIN DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL MALIGNANCIES
838 | A PHASE 1 TRIAL OF NX‐2127, A FIRST‐IN‐CLASS BTK DUAL‐TARGETED PROTEIN DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL MALIGNANCIES Open
View article: 848 | A PILOT STUDY OF EMAPALUMAB FOR THE TREATMENT OF CAR T‐CELL THERAPY‐ASSOCIATED PROLONGED CYTOPENIA
848 | A PILOT STUDY OF EMAPALUMAB FOR THE TREATMENT OF CAR T‐CELL THERAPY‐ASSOCIATED PROLONGED CYTOPENIA Open
View article: 53 | A PHASE II STUDY OF ACALABRUTINIB, LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH PREVIOUSLY UNTREATED INDOLENT B‐CELL LYMPHOMA
53 | A PHASE II STUDY OF ACALABRUTINIB, LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH PREVIOUSLY UNTREATED INDOLENT B‐CELL LYMPHOMA Open
View article: 845 | EPCORITAMAB WITH R‐miniCVP FOR OLDER UNFIT/FRAIL OR ANTHRACYCLINE‐INELIGIBLE ADULT PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA: A PHASE 2 TRIAL
845 | EPCORITAMAB WITH R‐miniCVP FOR OLDER UNFIT/FRAIL OR ANTHRACYCLINE‐INELIGIBLE ADULT PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA: A PHASE 2 TRIAL Open
View article: OT04 | GOLSEEK‐1: A PHASE 3, DOUBLE‐BLIND, RANDOMIZED STUDY OF GOLCADOMIDE + R‐CHOP VERSUS PLACEBO + R‐CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK, LARGE B‐CELL LYMPHOMA
OT04 | GOLSEEK‐1: A PHASE 3, DOUBLE‐BLIND, RANDOMIZED STUDY OF GOLCADOMIDE + R‐CHOP VERSUS PLACEBO + R‐CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK, LARGE B‐CELL LYMPHOMA Open
View article: 5 | LARGE B‐CELL LYMPHOMA MICROENVIRONMENT ARCHETYPE PROFILES (LYMPHOMAPS) IDENTIFY SUBGROUPS WITH GREATEST BENEFIT FROM CD19 CAR T‐CELL THERAPY
5 | LARGE B‐CELL LYMPHOMA MICROENVIRONMENT ARCHETYPE PROFILES (LYMPHOMAPS) IDENTIFY SUBGROUPS WITH GREATEST BENEFIT FROM CD19 CAR T‐CELL THERAPY Open
View article: Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy
Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy Open
Importance Cytokine storm (CS) is a hyperinflammatory syndrome causing multiorgan dysfunction and high mortality, especially in patients with malignant hematologic neoplasms. Triggers include malignant neoplasm–associated hemophagocytic ly…
View article: Tumor gene expression signatures associated with outcome in large B−cell lymphoma treated with CD19-directed CAR T−cell therapy (axicabtagene ciloleucel)
Tumor gene expression signatures associated with outcome in large B−cell lymphoma treated with CD19-directed CAR T−cell therapy (axicabtagene ciloleucel) Open
Introduction CAR T cell therapy provided transformative outcomes for patients with B-cell lymphoma; however, a large fraction of patients remains at risk for relapse, underlying the need to uncover mechanisms of resistance and predictive b…
View article: Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study Open
This phase 2 study evaluated mosunetuzumab plus cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin (Pola-M-CHP) vs Pola-rituximab (R)-CHP for first-line treatment of diffuse large B-cell lymphoma. Patients were randomized 2…
View article: Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas
Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas Open
Treatment options are limited for both relapsed/refractory primary and secondary central nervous system (CNS) lymphoma and the prognosis remains poor. Previous studies have shown the activity of Bruton tyrosine kinase inhibitors and progra…
View article: Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas
Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas Open
Background Select patients with relapsed/refractory aggressive B cell lymphoma may benefit from bridging radiation (bRT) prior to anti-CD19-directed chimeric antigen receptor T cell therapy (CAR-T). Here, we examined patient and treatment …